Abstract
Accumulating evidence points to the clinical relevance of the gut microbiota on outcome of immune checkpoint inhibitors (ICI). Recent work identified a gut oncomicrobiome signature centered by Akkermansia muciniphila (Akk) associated with favorable outcomes to ICI in advanced lung (NSCLC) and kidney (RCC) cancer patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
